Biogen pivots to Leqembi/Skyclarys and the Apellis deal to revive growth, but upside looks limited.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
Alpaca · SIPUpdated October 27 16:00 NY15 Minutes Delayed
STX Stock Slips Despite Q1 Beat, Dividend Hike — Analyst Flags Slowing Margin Growth
Yahoo2 Hours Ago
Cramer Says Micron Stock Does Whatever SK Hynix Does in Korea, and He Dislikes It
Yahoo3 Hours Ago
Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes
Yahoo3 Hours Ago
PYPL Stock On Track To Reverse 3 Weeks Of Gains: Analyst Says Turnaround Story Will Take Time
Yahoo3 Hours Ago
Eaton (ETN) Stock Looks Fairly Valued Despite Its 142% Run
Yahoo3 Hours Ago
